A gut-liver-on-chip model for simultaneous evaluation of isoniazid absorption and toxicity: A paradigm for drug exposure-toxicity assessment

Isoniazid (INH) is a first-line anti-tuberculosis drug; however, its dose-dependent hepatotoxicity limits clinical use. Conventional in vitro models lack the sequential gut absorption–liver metabolism interface, and animal models exhibit poor human translation. Here, we developed a gut-liver-on-chip model to simultaneously assess INH absorption and subsequent hepatotoxicity. A dual-organ chip was constructed with an intestinal barrier (Caco-2/HT29-MTX-E12, 9:1 ratio) and liver spheroids composed of HepG2, HUVEC-T1, phorbol myristate acetate-induced THP-1, and human hepatic stellate cells. INH was added to the intestinal chamber at concentrations of 10.6 mM and 15.8 mM. Drug concentrations in the liver chamber were quantified by high-performance liquid chromatography at 0, 2, 4, 8, 24, 32, and 48 h. After 48 h, intestinal barrier integrity was assessed by transepithelial electrical resistance (TEER), and hepatotoxicity was evaluated by measuring aspartate aminotransferase (AST), alanine aminotransferase (ALT), albumin (ALB), and propidium iodide (PI) staining of dead cells. INH was detected in the liver chamber within 2 h and reached equilibrium at 48 h in a dose-dependent manner. Both INH concentrations significantly increased AST and ALT levels, reduced ALB secretion, and increased PI-positive dead cells in liver spheroids compared with the control group (P < 0.05). TEER values decreased dose-dependently, indicating moderate intestinal barrier damage. In conclusion, this gut-liver-on-chip model enables dynamic monitoring of intestinal-to-liver drug transfer combined with endpoint assessment of organ-level toxicity, providing a human-cell-based proof-of-concept platform for preclinical safety evaluation of orally administered drugs with hepatotoxic potential.

Authors

Institutions

Publication Details

Journal
Biochemistry and Biophysics Reports
Published
2026-11-16
DOI
https://doi.org/10.1016/j.bbrep.2026.102895
Primary Topic
Drug-Induced Hepatotoxicity and Protection
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

A gut-liver-on-chip model for simultaneous evaluation of isoniazid absorption and toxicity: A paradigm for drug exposure-toxicity assessment

Xiaobing Zhou, Manman Zhao, Tian Lin, yu Yu
2 links
Biochemistry and Biophysics Reports
Drug-Induced Hepatotoxicity and Protection
article

A gut-liver-on-chip model for simultaneous evaluation of isoniazid absorption and toxicity: A paradigm for drug exposure-toxicity assessment

Xiaobing Zhou, Manman Zhao, Tian Lin, yu Yu
article en

Abstract

Isoniazid (INH) is a first-line anti-tuberculosis drug; however, its dose-dependent hepatotoxicity limits clinical use. Conventional in vitro models lack the sequential gut absorption–liver metabolism interface, and animal models exhibit poor human translation. Here, we developed a gut-liver-on-chip model to simultaneously assess INH absorption and subsequent hepatotoxicity. A dual-organ chip was constructed with an intestinal barrier (Caco-2/HT29-MTX-E12, 9:1 ratio) and liver spheroids composed of HepG2, HUVEC-T1, phorbol myristate acetate-induced THP-1, and human hepatic stellate cells. INH was added to the intestinal chamber at concentrations of 10.6 mM and 15.8 mM. Drug concentrations in the liver chamber were quantified by high-performance liquid chromatography at 0, 2, 4, 8, 24, 32, and 48 h. After 48 h, intestinal barrier integrity was assessed by transepithelial electrical resistance (TEER), and hepatotoxicity was evaluated by measuring aspartate aminotransferase (AST), alanine aminotransferase (ALT), albumin (ALB), and propidium iodide (PI) staining of dead cells. INH was detected in the liver chamber within 2 h and reached equilibrium at 48 h in a dose-dependent manner. Both INH concentrations significantly increased AST and ALT levels, reduced ALB secretion, and increased PI-positive dead cells in liver spheroids compared with the control group (P < 0.05). TEER values decreased dose-dependently, indicating moderate intestinal barrier damage. In conclusion, this gut-liver-on-chip model enables dynamic monitoring of intestinal-to-liver drug transfer combined with endpoint assessment of organ-level toxicity, providing a human-cell-based proof-of-concept platform for preclinical safety evaluation of orally administered drugs with hepatotoxic potential.

Biochemistry and Biophysics ReportsVol. 48
China Pharmaceutical University (CN), Chinese Academy of Medical Sciences & Peking Union Medical College (CN), China Banking Regulatory Commission (CN), National Institutes for Food and Drug Control (CN), State Key Laboratory of Natural Medicine (CN)
Good health and well-being
Drug-Induced Hepatotoxicity and Protection
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon